Chandra Kant Singh
Kushneet Kaur Sodhi- Department of Zoology, University of Delhi, Delhi, India
COVID-19, one of the worst-hit pandemics, has quickly spread like fire across nations with very high mortality rates. Researchers all around the globe are making consistent efforts to address the main challenges faced due to COVID-19 infection including prompt diagnosis and therapeutics to reduce mortality. Conventional medical technology does not effectively contain the havoc caused by deadly COVID-19. This signals a crucial mandate for innovative and novel interventions in diagnostics and therapeutics to combat this ongoing pandemic and counter its successor or disease if it were ever to arise. The expeditious solutions can spring from promising areas such as nanomedicine and nanotechnology. Nanomedicine is a dominant tool that has a huge potential to alleviate the disease burden by providing nanoparticle-based vaccines and carriers. Nanotechnology encompasses multidisciplinary aspects including artificial intelligence, chemistry, biology, material science, physical science, and medicine. Nanoparticles offer many advantages compared to larger particles, including better magnetic properties and a multiplied surface-to-volume ratio. Given this, the present review focuses on promising nanomedicine-based solutions to combat COVID-19 and their utility to control a broad range of pathogens and viruses, along with understanding their role in the therapy, diagnosis, and prevention of COVID-19. Various studies, reports, and recent research and development from the nanotechnology perspective are discussed in this article.
Introduction
Infectious diseases present a global threat to mankind after a disaster of cataclysmic proportions or a nuclear war. Infectious diseases are the main reason for increasing the morbidity rate, plaguing humanity, and shaping human evolution in the process (Bloom and Cadarette, 2019) and are one of the most important agents leading to premature death, especially in the developing world (Chandler, 2019). Modernization has made mankind complacent about the threat due to the increased access to medical healthcare, vaccines, and sanitization techniques. Sentinel organizations and epidemiological experts have time and again provided abundant warnings about the catastrophe related to infectious disease. Microorganisms do not need a visa to travel to different parts of the world and do not understand geopolitical boundaries. Furthermore, climate change and globalization have aggravated the concern about the spread of infections and pathogens. The newest epidemics such as Ebola, SARS, H1N1, and MERS were an alarming signal for the entire world that the viral pathogens pose a serious threat globally (Vazquez-Munoz and Lopez-Ribot, 2020). The recent pandemic that has hit the entire world is coronavirus disease, commonly known as COVID-19, caused by the SARS-CoV-2 virus (Kaushik, 2021). The virus can be transmitted directly from an infected patient via coughing, sneezing, and physical contact. Major symptoms of COVID-19 include fever, sore throat, sneezing, coughing, breathlessness, and tiredness (Figure 1). Moreover, patients having any secondary ailment such as blood pressure, coronary heart disease, or diabetes are potentially at high risk (Rashidzadeh et al., 2021).
FIGURE 1. Structure of SARS-CoV-2 and the associated symptoms.
Ever since the coronavirus was declared a pandemic on 11 March 2020, many new variants, such as Omicron, Delta, and many more rapidly spreading variants of concern, have posed a major challenge (Cucinotta and Vanelli, 2020). COVID-19 impacted the whole world with the economies collapsing. The first case was observed in December 2019 in Wuhan, where pneumonia-like symptoms were observed in locals. In the first week of January 2020, this new virus was found to be like coronavirus (Ahmad et al., 2020; Sodhi and Singh, 2022).
The surge in cases was exponential further suggesting that the transmission occurs via sneezing and coughing from asymptomatic and symptomatic patients. The coronavirus remains on the surfaces for a long period if not destroyed using disinfectants (Koo et al., 2020). As of October 2022, at least 629 million COVID-19 cases and 6.59 million related deaths had been reported globally according to the World Health Organization (https://www.who.int). A certain degree of structural homology and sequence similarity between SARS-CoV-2, SARS-CoV in 2002, and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 was identified (Sadeghi et al., 2021). SARS-CoV-2 transmissibility is higher than that of other viruses (Saylan and Denizli, 2020). The disease severity varies from mild respiratory illness to acute respiratory syndrome affecting the lungs (Chhikara et al., 2020). Infections of COVID-19 can affect the cardiovascular system (Widjaja et al., 2021), kidneys (Esmaeilzadeh et al., 2021), central nervous system (Esmaeilzadeh et al., 2021), gastrointestinal tract, and liver (Gavriatopoulou et al., 2020). An uncontrolled cytokine storm can lead to the failure of multiple organs, strokes, and heart failure (Rabaan et al., 2021). Many strategies for controlling the infectious disease have emerged, such as lockdowns, social distancing, quarantine, various disinfection protocols, and antiviral treatment methods (Bhaskar et al., 2020).
The conventional treatments of viral pathogenic infections can fade away due to the emergence of novel strains of the virus which emerge because of mutations in the virus (Strasfeld and Chou, 2010). Certain antiviral drugs can be used for the treatment of new strains of viruses (Jackman et al., 2016). However, novel drugs take an extended time to be approved for their safety and efficacy, so the development of new drugs is lagging (Chen et al., 2020). Multidisciplinary research is required for novel approaches for antiviral treatments along with alternative antiviral therapies, targeting the different phases in viral replication (Revuelta-Herrero et al., 2018; Mohammadi Pour et al., 2019). Nanotechnology harnessed immense attention and is explored for possible use in the treatment of viral infections (Szunerits et al., 2015; Singh et al., 2017; Lembo et al., 2018).
The unexpectedness of the SARS-CoV-2 outbreak has retarded the modalities to regulate the damage. The policies including social distancing, unprecedented strict lockdown, vaccination, and wearing face masks have been introduced to control the contagious disease (Chaudhary et al., 2021). Research is focused on modeling innovative point-of-care practices for timely diagnosis and therapeutics to control pandemic-initiated mortalities and morbidities. These strategies are employed, but their success varies spatially and is influenced by environmental factors. Various environmental factors, such as relative humidity, ammonia concentration, and particulate matter, are responsible for the spread of COVID-19 and associated mortality (Bollyky et al., 2022). In the study of Chaudhary et al. (2022a), correlation analysis was used to study the role of environmental factors in the progression and severity of COVID-19. A statistical analysis indicates the correlation between COVID-19-associated mortalities and various environmental factors. The regression model throughout the strategic lockdown has suggested the prominent triumph of unparalleled constraints in Delhi in the form of restrictions on movement. Particulate matter is anticipated to be an important risk promoting the severity and outbreak of COVID-19. The hotspot mapping of airborne ammonia, particulate matter, and relative humidity was also identified using the regression model and mapping the ambient concentration. Areas in the capital undergoing rapid construction, industrial activities, and vehicular emissions are the major hotspots.
Modernization and urbanization can increase the risk of many unseen pandemics in the future. COVID-19 has shaken the world, but still, efficient antiviral treatment options are lacking. COVID-19 presents three major challenges: timely diagnosis, prevention, and treatment (Chaudhary et al., 2021). The major concern worldwide is the determination of an outbreak at an initial stage, which has led to the development of strenuous efforts in the development of point-of-care diagnosis, especially the advanced rapid test, tests based on artificial intelligence, and computed tomography (CT) scans. Forthcoming measures of detection, cure, and prevention have been extensively researched, and advancements have been made using nanotechnology (Chaudhary et al., 2022b). Diverse formulations based on the concept of nanotechnology are considered promising for vaccine development (Cascella et al., 2022). Delivery of nanomaterial-based formulations commends the active agent concentration, silencing RNA, vaccines, antiviral species, and antibodies at the sites of infection generating a basic potentiation of the immune system (Ruiz-Hitzky et al., 2020). Biohybrid nanomaterials are based on polysaccharides and fibrous clay assembly and show a promising environment for viral particles, aiding in their binding to the biohybrid material and helping in conserving their bioactivity. Nanoparticle-based formulations are used in vaccination and for intranasal administration for coronaviruses and influenzas (Al-Halifa et al., 2019).
Nanotechnology has a lot of potentials, and it can be used for the development of medicines and drugs at the nanoscale and can be utilized in the development of novel approaches to deal with viral infections. This can be proved to be a cutting-edge technology that can be used for the successful treatment of COVID-19, but it can also be used to improve the already existing diagnostic and therapeutic strategies (Chintagunta et al., 2021). Nanotechnology is the application of devices and materials in which at least a single dimension is lower than 100 nm. The nanotechnology’s application in medicine is called nanomedicine, which comprises the nanomaterials used in the control, prevention, diagnosis, and treatment of diseases (Yayehrad et al., 2021). Nanoparticle research has gained much attention in the last decade due to the advantages of nanoparticles such as small size, multifunctionality, better solubility, adaptability, production of better and safer drugs, nanomedicines, and early diagnosis of diseases (Bhavana et al., 2020; Pandian et al., 2021).
Nanotechnology can help combat COVID-19 by avoiding viral contamination by designing nano-based vaccination for boosting both humoral and cell-mediated immunity, designing personal protective equipment (PPE) kits and disinfectants to increase the safety of front-line workers, designing sensitive and specific nano-based sensors for quick immunological response, and developing novel drugs, having enhanced antiviral activities, sustained release, tissue specificity, and reduced toxicity (Balkrishna et al., 2021).
Nano-formulations can be used to enhance the target delivery and therapeutic efficacy of the antivirals (Singh et al., 2017; Lembo et al., 2018). There is a lack of therapeutic choices for the treatment of viral infections, so plant metabolites offer a lucrative option for their treatment. However, plant metabolites have poor solubility and availability, so they are often combined with nano-based carriers for better therapeutic effects (Watkins et al., 2015; Gera et al., 2017; Praditya et al., 2019). Not only in therapeutics but also in diagnostics, many nano-based sensors are used that have high sensitivity and specificity (Mokhtarzadeh et al., 2017). Next-generation vaccines are also available which are based on nanomaterials, offering improved antigen specificity, control release, and target delivery (Vijayan et al., 2019). Delineation of mechanisms involved by which the virus infects the host cell is also carried out (Campos et al., 2020). Figure 2 shows the applications of nanomedicine to fight COVID-19.
FIGURE 2. Applications of nanomedicine to fight COVID-19.
Many studies have reported nanotechnology used in the treatment of chronic illnesses such as cancer, but very few studies report their use in addressing the challenges imposed by COVID-19. So, given this, the present review critically discusses various nanotechnology-based diagnostic and therapeutic strategies for managing the SARS-CoV-2 variants of concern.
Role of nanotechnology in COVID-19 diagnostics
Nanostructured systems aid in the advancement of COVID-19 detection, increasing their sensitivity and specificity for signal amplification in a reverse transcription–polymerase chain reaction (RT-PCR) and prophylaxis for vaccines as adjuvants (Krishnan et al., 2021). Nanoparticles play a therapeutic and vital role, especially during different stages of COVID-19 pathogenesis because of the inhibition potential for the preliminary attachment and membrane fusion when the virus enters and in the protein fusion of the infected cell (Vahedifard and Chakravarthy, 2021). Nano-encapsulated antiviral drugs are more effective in the activation of the intracellular mechanism which leads to irretrievable harm to viruses and inhibits the cellular machinery of the viruses by impairing their replication, transcription, and translation. Novel nano-technological methods can help detect COVID-19 infection. A few problems are associated with the already existing protocols; for example, the RT-PCR used for testing the asymptomatic COVID-19 patients was not available in many non-urban centers. The WHO stated the urgency for novel diagnostic kits for detecting SARS-CoV-2 (Kamat et al., 2021; Fernandes et al., 2022).
COVID-19 detection using loop-mediated isothermal amplification
Loop-mediated isothermal amplification is a rapid method that has high specificity and sensitivity (Kim et al., 2022). Xu J. et al. (2020) showed that magnetic nanoparticles can be used in RT-PCR diagnosis and for extracting SARS-CoV-2 RNA. Magnetic nanoparticles are used in this technique which are functionalized with poly amino ester, and the extracted RNA was absorbed on magnetic nanoparticles containing carboxyl groups. The interaction of the RNA magnetic nanoparticle and carboxyl groups is used for the analysis (Xu L. et al., 2020). They are directly used without the elution of viral RNA from the magnetic beads. It is a time-saving mechanism and protects from any contagious risks. The magnetic nanoparticles were used by the same group in a different study, where the virus was isolated instead of eluting viral RNA. The enriched viral particles are bound tightly to nanoparticles because of target receptors. The magnetic nature of the nanoparticles is attained by the encapsulation of paramagnetic iron oxide. They help in the detachment of the virus from nanoparticles with the aid of an external magnet and detect the virus by immunochromatographic strip tests, cell-based tittering assays, and quantitative RT-PCR (Mujawar et al., 2020; Shan et al., 2020).
Fifth-generation biosensors for COVID-19 detection
Current health crises because of infectious diseases including COVID-19 and monkeypox have raised the model of multifunctional and portable biosensors embedded in the solo chip. Conventional diagnostics methods are costly, complex, and time-consuming; therefore, biosensors are used as a lucrative alternative as they possess applications in the pharmaceutical and healthcare industries (Verma and Bhardwaj 2015). Biosensors are installed for the recognition of multiple diseases, prevention, health observation, and rehabilitation of patients (Dwivedi et al., 2021). The fifth-generation biosensors can be used for studying advanced nanomaterials, and they can be integrated with intelligent and rapid data processing strategies and packed in portable modules for various healthcare applications (Wu et al., 2022; Zhang et al., 2021). Biosensors aid to integrate the pioneering functional materials having manageable physicochemical attributes and ideal machine processability. The 2D metal nitrides and carbides show promising performances due to their adjustable physicochemical properties and rich surface functionalities. The biosensor hybridization along with diversified nanomaterials provides challenges for the commercialization of stability due to oxidation. Biosensors have been interfaced with modern-age technologies, including 5G communication and artificial intelligence (AI), for heading toward the hospital-on-chip (HOC) modules. Graphene and its derivatives, metal nitrides and carbides (MXenes), and borophene have emerged as excellent biosensing platforms with a high specific surface area with enhanced detection and monitoring efficacies (Zhang et al., 2021; Chaudhary et al., 2022a; Chaudhary et al., 2022c). MXenes demonstrate enormous potential for monitoring and detecting diverse biomolecules and encompassing electrochemical, optical, and plasmonic modules (Sheth et al., 2022). The infectious and fatal diseases have certainly burdened the already existing healthcare services globally and resulted in mortalities, so the primary concern in the post-COVID-19 era is the early diagnosis of contagious diseases to strengthen their treatment and curtail the spread (Chaudhary et al., 2022b; Noh et al., 2022). The consequences of infectious diseases can be managed via early diagnosis of respective biomarkers, so as to enhance their therapeutic efficiency (Cherusseri et al., 2022; Markandan et al., 2022). Timely detection via point-of-care (POC) diagnostics is highly advantageous, as it is highly efficacious and simple. Nanomaterials can also be utilized to enhance the functioning of the POC devices for improved efficiency. Table 1 and Figure 3 show the use of nanotechnology in the prompt diagnosis of COVID-19.
TABLE 1. Use of nanotechnology in the prompt diagnosis of COVID-19.
FIGURE 3. Rapid diagnosis of COVID-19 using biosensors.
Nanomedicine's role in COVID-19 treatment
Nanomedicine influences every field of medicine and is a dynamic tool for the development of novel therapeutics, medical imaging, nanotherapeutics, vaccines, and biomaterials for the regenerative medication (Varahachalam et al., 2021). Nanomedicine is an amalgamation of nanotechnology and medicine and uses nanoparticles in therapeutic or diagnostic applications (El-Sayed and Kamal, 2020). Soft nanomaterials are attained from lipids, proteins, polymers, and surfactants and are often applied in nanomedicine for drug delivery. There are also prerequisites for the use of nanomaterials (Devadasu et al., 2013). Several drug-based nanoparticles are under clinical trials for diseases such as neurodegenerative diseases, cancer, cardiovascular, infectious, and inflammatory illnesses (Yetisgin et al., 2020). Nanoparticles can aid in active or passive drug targeting along with controlled drug release, which affects the safety and efficacy of the treatment. Metal nanoparticles can be used in nanomedicine, due to their antibacterial, antiviral antifungal, and antiparasitic activities (Singh et al., 2019). Pathogenic bacteria develop resistance to already used antimicrobials, which led to the development of nanotechnology-based antimicrobial therapy, such as metal-based antimicrobials, which are effective in the treatment of superbugs. Similarly, the incidence of a new strain of viruses and heterogeneity has likewise necessitated advanced and innovative therapies. Since nanotechnology offers specific targeting, it can be used for antiviral therapy (Teixeira et al., 2018).
Nanoparticles can be used to combat SARS-CoV-2 by targeting mechanisms that affect the viral entry inside the host until they get activated. By blocking the surface proteins on the virus, the virus gets inactivated, so nanoparticles are designed specifically for virus-expressed proteins and could diminish viral internalization (Goscianska et al., 2022). Metal nanoparticles can block the virus’s attachment to the host cell, thereby inhibiting the internalization of the virus and impairing the replication of the virus during viral entry. Silver (Ag), titanium (Ti), zinc (Zn), and gold (Au) have shown results against the influenza virus, herpes simplex virus, transmissible gastroenteritis virus, Zika virus, HIV, and monkeypox virus (Mainardes Diedrich, 2020).
Organic nanoparticles are used to improve the bioavailability of the antivirals such as dapivirine, zidovudine, efavirenz, and acyclovir. The organic nanoparticles are also important to promote effective drug delivery and help in targeted antiviral delivery (Delshadi et al., 2021). Nanoparticles overcome antiviral limitations to specific targeting which results in cytotoxicity of the host cell. Many clinical trials have been conducted for COVID-19, and antimicrobials like ribavirin, lopinavir, remdesivir, chloroquine, and ritonavir were tested and showed promising results against SARS-CoV-2 (Oroojalian et al., 2020). Nanoencapsulation of these drugs may aid in the development of safer treatments for viral diseases such as COVID-19. The nanoparticles in the case of viral diseases are underused and not fully explored, which came to light during the pandemic (Pandey et al., 2020).
Nanomedicine can deliver a general platform that can be improved simply to ensemble the application in necessity. This can be displayed during this brief span since the pandemic started. For example, with the change in the therapeutic particle encapsulated inside synthetic or natural nanoparticles, a different vaccine for the treatment of COVID-19 can be developed. Specific regulations are lacking for the approval of nanomedicine, and novel nanomedicine must undergo full clinical trials (Germain et al., 2020). During the hard times amidst the coronavirus, nanomedicine has outshined other fields, and the knowledge has provided science with innovative therapeutic modalities for the pandemic. The clinical development of nano-products is necessary to solve the clinical needs which are beyond oncology. It is vital to report the lacunae facing the development of nanomedicine such as aspects, especially related to the nanotoxicology of new nanomaterial classes along with the global explanation on monitoring approval for both the biological activity and physicochemical characterization, especially for multifunctional products (Hashemi et al., 2021).
Nanomedicine with a size of up to 200 nm is a beneficial cargo fabricated using a suitable drug nanocarrier as a beneficial agent (Moghimi et al., 2005; Karimi et al., 2016). Magnetic nanoparticles can be used to control and manage the virus pathogen even in the brain as nanomedicine can cross any barriers via the following measures: 1) nanomedicine functionalization with specific receptors for the brain, 2) using ultrasound as external stimulation, and 3) a non-invasive method which can use a magnetic drug delivery system (Mitchell et al., 2021; Mohammadi et al., 2022). Magnetic nanomedicine is designed to deliver the drugs at a specific site to control release by applying peripheral stimulation like a magnetic field, and the drug release sequence can be strategized according to the prerequisite of the disease condition (Ashwini et al., 2022; Naghdi et al., 2022). The nanomedicine performance depends mainly on the choice of a multifunctional stimuli-response drug nanocarrier, opto-magnetic, magneto-plasmonic nanosystem, and magneto-liposome (Kaushik, 2021). Nanomedicine can be vital for the recognition of disease progression and drug distribution. Manipulative magnetic nanomedicine (MMN) is a possible upcoming therapy wherein control over delivery and routine is mandatory (Kaushik, 2021). MMN can aid in the identification and elimination of the SARS-CoV-2 virus for the management of viral symptoms and infection. In addition to the elasticity in using the therapeutics of the choice, these unscrupulous nanomedicines can be recognized as a long-interim treatment for the SARS-CoV-2 infection, where immune supportive agents can stay for a long period in the body without fabricating any ill effects. MMN proves to be a compulsory remedy, and emphasis on its expansion must be made by the forthcoming study with the resulting objectives: 1) exploration of stimuli-responsive MMN for precise delivery and release; 2) confirmation of the site of drug delivery and release by using image-guided therapy; 3) delivery of drug in the gut and blood–brain barriers using the magnetic guided approach; and 4) the customization of MMN according to the medical history and disease profile of the patient, for example, selection of CRISPR-Cas and anti-SARS-CoV-2 virus based on the genomic profiling of the patient (Kaushik, 2021). The customization of the MMN for extended therapeutics allows the release of the drug for a longer time to manage post-COVID-19 effects (Jayant et al., 2018; Kaushik et al., 2018; Kaushik et al., 2019; Tomitaka et al., 2019; Kaushik, 2021).
SARS-CoV-2 infection is a manifestation of many symptoms. COVID-19 infection requires extensive treatment, and even after discharge from the hospital, the patient may have the complicated condition for a longer time (Dao et al., 2021). Conventional antiviral drugs cannot be used for the treatment of adverse symptoms. Micro-needle-based vaccine delivery is used for the management of COVID-19 infection. Initial trials are promising, but a lot more must be carried out for animal-based trials, followed by FDA approval. MNM can be promoted against COVID-19 effectively, and research is required in this field to traverse the path from in vitro to in vivo and finally to clinical and human trials, and FDA approval is required for public use. For the development of anti-COVID-19 infection therapy, critical safety-related risk assessments should be assessed. Artificial intelligence introduction can be a good option, because of the use of bioinformatics to perform big data analysis and avoid hit-and-trial approaches (Gage et al., 2021; Kaushik, 2021).
Artificial intelligence-based face masks to combat COVID-19
Since the old civilizations, face masks are a vital component of human lives. Face masks are used as an economically viable tool and create a sense of communal unity and combat health hazards (Chaudhary et al., 2022d). The use of face masks is still not normalized because of manufacturing limitations, solid waste production, and unawareness. The limitations have been overcome by the choice of material utilized for manufacturing (Ganesapillai et al., 2022). Masks are designed from textiles such as biomaterials and nanomaterials in the present-day market. Face mask respirators (FMRs) are engineered using nanomaterials and are advantageous as they have a high specific surface area, unique physicochemical properties, multiple usages, good breathability, and pathogen-detecting and -scavenging capabilities (Forouzandeh et al., 2021). FMRs are vital as they break the chain of viral infection, thereby protecting the community spread (Chaudhary et al., 2022a). The SARS-CoV-2 viral infection is correlated with fungal and microbial infection. Mucormycosis spread in various countries is a consequence of COVID-19. The variants of concern like Omicron have a higher spread rate and have challenged the diagnosis, prevention, and therapeutics for COVID-19 (Bhatt et al., 2021). More novelties, especially in designing the preventive FMRs are crucial with intelligent and smart features. The inclusion of the contemporary technologies of nanotechnology, Internet-of-Things (IoT), artificial intelligence (AI), and machine learning can be useful in architecting the FMRs (Umapathi et al., 2021). The IoTs can be used and integrated with nanomaterials for the fabrication of next-generation FMRs having AI techniques. The sensors can also be incorporated into the FMRs to observe human behavioral and physiological signals. Even in the remotest part of the world, nanomaterial-based biosensors can be integrated into FMRs using minute radio antennas used for the diagnosis of COVID-19 (MacIntyre and Chughtai et al., 2020). The radio antenna integrated into the FMRs can aid in the recording of COVID-19 cases. The integration of AI makes the technology available to any user and helps in the management and monitoring of COVID-19. With the help of AI, smarter FMRs can be designed and can control the massive spread of COVID-19 (Manickam et al., 2022). The Global Positioning System (GPS) should be incorporated to assess the patient’s routine and set up early warnings and advice (Chaudhary et al., 2022b). A smart filtering facepiece (FFP2) mask with an opto-chemical sensor integrated and driven via a smartphone is used for monitoring CO2 inside the mask. This mask is fabricated specifically to tackle the health effects that arise due to prolonged use of the face mask. Chen et al. (2022) reported the use of an FMR based on electrospun polyetherimide (PEI) electret non-woven. It is a bi-functional mask that removes particulate matter and is also used for the generation of electricity. It is capable of self-sterilization and has features such as biodegradability, transparency, breathability, hydrophobicity, and biocompatibility (Chen et al., 2022).
Application of 3D printing to combat COVID-19
The demands for medical technology have exceptionally increased since the arrival of the global pandemic. Innovative 3D printing, which was initially started with no practical utilization, has now been accepted in various industries, for example, engineering and healthcare (Larrañeta et al., 2020). Three-dimensional printing is used to produce face shields, components of the ventilator, and masks which were of utmost importance during the pandemic scenario. In this technique, products are fabricated utilizing digital CAD files using layer-by-layer techniques (Munaz et al., 2016; Irfan Ul Haq et al., 2020). It is highly favored in the medical field because of its customization. This technique is beneficial as it helps in adapting to variations as per the circumstances of the patient (Marro et al., 2016). The software helps in conceptualizing medical equipment, which is later 3D-printed with less cost and time. The rapid prototyping of this technique permits a rapid mobilization of the equipment (Marro et al., 2016).
A 3D antibacterial swab made up of a bio-cellulose lattice structure is used for the detection of COVID-19 as the use of a nasopharyngeal swab poses a serious problem. Nasopharyngeal swabs which are 3D-printed deliver a lucrative and fast substitute as compared to conventional nasopharyngeal swabs (Haleem et al., 2021). Three-dimensional printing is vital for hospitals as it is remarkably positioned to elucidate the instant needs and acts quickly on them by operating together between industry and hospital and helping in saving valuable time to address the shortage needs in hospitals (Javaid & Haleem, 2021).
Three-dimensional-printed face masks are vital. One example is the Copper3D NanoHack mask which creates the borders of the community-created tactics and the necessity for the improvement of design which is based on the availability of the technical base and local testing. A polylactic acid (PLA) filament is used for 3D printing, and it is hand-assembled into the final 3D configuration when heated at 55–60°C through a hair dryer or hot air (Belhouideg, 2020). The mask consists of a simple port for air intake with the insertion of two reusable filters, and the filter can be kept in place by a screw-in cover (Tino et al., 2020). PPE is also used in 3D printing. The pandemic significantly increased the use of PPE, especially its use in healthcare has significantly increased. There is a surge in the propagation of the 3D printing method mainly due to an increase in the ability to produce PPE via organized means.
Three-dimensional printing offers many advantages, but there are also a few limitations to 3D printing (Clifton et al., 2020). The major problem is that the mechanical hindrance of particles can only be simulated to a degree, but the multiplication of the electrostatic properties of the filter with 3D materials is a major challenge. Thermoplastic filaments which are essential for fused deposition modeling (FDM) printing vary extremely in the composition of materials, porosity, and environmental stability (Katkar et al., 2018). FDM filaments grasp ambient moisture, which could stance an absurdly amplified risk for virus transmission during reuse (Jurischka et al., 2020). Table 2 shows the nanomedicine formulations for the COVID-19 therapeutics.
TABLE 2. Nanomedicine formulations for the COVID-19 therapeutics.
Challenges to the use of nanotechnology in COVID-19 treatment
Respiratory infections are one of the most common reasons for deaths worldwide. Although there are vaccines and drugs available now to prevent or treat COVID-19, many existing drugs are repurposed drugs that are effective against very few pathogens (Saha et al., 2020). Along with the conventional approaches, researchers are trying to develop suitable nanomedicines. This review highlights the role of nanomaterials in diagnosis, prevention, and vaccine production, and their role in the treatment of patients relapsing after finishing a conventional antiviral treatment (Yetisgin et al., 2020). Nanoparticle development is a lucrative option due to its surface charge, shape, size, large surface-to-volume ratio, and biological and functional properties. The conventional therapies do not appear to be well-equipped in handling the pandemic. Therefore, we must prioritize diversifying our research to seek a permanent solution that can fight future pandemics. Nanotechnology can help develop measures to reduce SARS-CoV-2 infectivity and help in prompt diagnosis of the contagious disease (Harish et al., 2022). Sanitizers based on nanotechnology display a broad and potent antimicrobial and antiviral activity; therefore, they can be instrumental in improving safety and uplifting healthcare facilities, especially in developing countries (Sportelli et al., 2020). Nanotechnology plays a crucial role in the design of detection kits, vaccines, and therapeutics to fight the COVID-19 variants of concern. The therapeutic use of antiviral drugs based on nanotechnology is an effective remedial option; as more research options are accessible, it can further be expanded (Varahachalam et al., 2021). The antimicrobial potency of drugs can be enhanced using nanomaterials for the treatment of secondary infections. Nanotechnology along with in silico drug designing, artificial intelligence, and synthetic biology is still in a nascent stage, especially with regard to their applications. Most of the translational research on nanotechnology and other promising domains is utilized for diseases such as cancer (Kamat et al., 2021). Nanotechnology offers many limitations in managing COVID-19, as it fails to eradicate viral particles within the body. The lack of research to study the in vivo behavior of these nanoparticles inside the body, the immunological response to these nanomaterials and their systemic clearance, and side effects is not well understood (Rai et al., 2021). With the severity of the ongoing pandemic and the sudden damage it has caused, many nations are unwilling to risk their resources on unconventional technologies. RNA viruses are prone to mutations and recombination which makes them more dangerous to humans and can be considered a global threat (Hu et al., 2021). Nanomaterials, especially due to their nano-size can cause respiratory ailments and lung problems, and this aspect should be kept in mind while designing the nanoparticle. Oxidative stress, fibrosis, immunotoxicity, inflammation, potential cell toxicity, and genotoxicity of the nanoparticles are important issues that must be solved before reaching patients (Di Giampaolo et al., 2021).
Conclusion
Academia and research industries all over the world are working to alleviate the health crisis caused by COVID-19. Nanoscience and nanotechnology tools offer a useful approach to the present global priority. Basic research, which starts from the computational simulation to study the interaction of the virus with nanomaterials, is vital to obtain data on the viral particle’s nanostructure and their mechanisms of infection. Safe and judicious use of nanomaterials is vital, as almost all the studies conducted so far have evaluated the treatment using only the in vitro approaches. Nanomaterials’ behavior and fate can change upon reaching blood circulation. Thus, we should rely on in vivo models for long-term exposure to comprehend the behavior of the nanoparticles in the body. There is a need to accelerate the deployment of suitable approaches which can be used to prevent, diagnose, and treat infectious diseases. Advances in the treatment and diagnostics of COVID-19 are continuing quickly, but novel viruses such as coronavirus and their mutants are more aggressive than the typical flu. Antiviral drug cocktails helped patients with moderate COVID-19 symptoms and stopped the multiplication of the virus. The use of nanocarriers can help in the transportation of these drugs, and their administration through the nasal route could save many lives. Nanotechnology advancement provides a lucrative solution for the rapid detection of the infection and helps to develop antigen and antibody testing kits that are useful, especially for asymptomatic patients. Lipid nanoparticles, viral-based vaccines, hard nanomaterials, which are used for viral detection, and the fabrication of PPE are at the lead in the pandemic. These technologies stemming from nanomedicine are very promising and lay the platform to deal with unforeseen pandemics in the future. It is a big push for the application of nanomedical technologies and eventually becomes an incentive for industry stakeholders, funding, and regulatory bodies to invest further in this budding field. Continuous research is required to improve the characteristics of these diagnostic, preventive, and therapeutic modalities via the use of nanotechnology which is the primary focus of the researchers. Researchers identifying the nanomaterials for medical sciences must warrant that nanomaterials can deal with any future pandemics.
Author contributions
CKS: writing and editing. KKS: conceptualization, writing, editing, and supervision.
Acknowledgments
The authors would like to thank the University of Delhi.
Conflict of interest
The reviewer VC declared a shared parent affiliation with the authors to the handling editor at the time of review.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ahmad, T., Baig, M., and Hui, J. (2020). Coronavirus disease 2019 (COVID-19) pandemic and economic impact. Pak. J. Med. Sci. 36, S73–S78. doi:10.12669/pjms.36.covid19-s4.2638
Ahmed, S. R., Nagy, É., and Neethirajan, S. (2017). Self-assembled star-shaped chiroplasmonic gold nanoparticles for an ultrasensitive chiro-immunosensor for viruses. RSC Adv. 7 (65), 40849–40857. doi:10.1039/c7ra07175b
Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., and Archambault, D. (2019). Nanoparticle-based vaccines against respiratory viruses. Front. Immunol. 10, 22. doi:10.3389/fimmu.2019.00022
Ashwini, T., Narayan, R., Shenoy, P. A., and Nayak, U. Y. (2022). Computational modeling for the design and development of nano based drug delivery systems. J. Mol. Liq. 368, 120596. doi:10.1016/j.molliq.2022.120596
Asif, M., Ajmal, M., Ashraf, G., Muhammad, N., Aziz, A., Iftikhar, T., et al. (2020). The role of biosensors in coronavirus disease-2019 outbreak. Curr. Opin. Electrochem. 23, 174–184. doi:10.1016/j.coelec.2020.08.011
Balkrishna, A., Arya, V., Rohela, A., Kumar, A., Verma, R., Kumar, D., et al. (2021). Nanotechnology interventions in the management of COVID-19: Prevention, diagnosis and virus-like particle vaccines. Vaccines 9 (10), 1129. doi:10.3390/vaccines9101129
Belhouideg, S. (2020). Impact of 3D printed medical equipment on the management of the Covid19 pandemic. Int. J. Health Plann. Manage. 35 (5), 1014–1022. doi:10.1002/hpm.3009
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., et al. (2020). Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM consortium position paper. Front. Immunol. 11, 1648. doi:10.3389/fimmu.2020.01648
Bhatt, K., Agolli, A., Patel, M. H., Garimella, R., Devi, M., Garcia, E., et al. (2021). High mortality co-infections of COVID-19 patients: Mucormycosis and other fungal infections. Discoveries 9 (1), e126. doi:10.15190/d.2021.5
Bhavana, V., Thakor, P., Singh, S. B., and Mehra, N. K. (2020). COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. Life Sci. 261, 118336. doi:10.1016/j.lfs.2020.118336
Bloom, D. E., and Cadarette, D. (2019). Infectious disease threats in the twenty-first century: Strengthening the global response. Front. Immunol. 10, 549. doi:10.3389/fimmu.2019.00549
Bollyky, T. J., Hulland, E. N., Barber, R. M., Collins, J. K., Kiernan, S., Moses, M., et al. (2022). Pandemic preparedness and COVID-19: An exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from jan 1, 2020, to sept 30, 2021. Lancet 399 (10334), 1489–1512. doi:10.1016/s0140-6736(22)00172-6
Campos, E. V., Pereira, A. E., De Oliveira, J. L., Carvalho, L. B., Guilger-Casagrande, M., De Lima, R., et al. (2020). How can nanotechnology help to combat COVID-19? Opportunities and urgent need. J. Nanobiotechnology 18 (1), 1–23. doi:10.1186/s12951-020-00685-4
Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., and Di Napoli, R. (2022). “Features, evaluation, and treatment of coronavirus (COVID-19),” in Statpearls [internet] (Treasure Island (FL): StatPearls Publishing).
Chandler, C. I. (2019). Current accounts of antimicrobial resistance: Stabilisation, individualisation, and antibiotics as infrastructure. Palgrave Commun. 5 (1), 53–13. doi:10.1057/s41599-019-0263-4
Chaudhary, V., Ashraf, N., Khalid, M., Walvekar, R., Yang, Y., Kaushik, A., et al. (2022a). Emergence of MXene–polymer hybrid nanocomposites as high-performance next-generation chemiresistors for efficient air quality monitoring. Adv. Funct. Mat. 32 (33), 2112913. doi:10.1002/adfm.202112913
Chaudhary, V., Bhadola, P., Kaushik, A., Khalid, M., Furukawa, H., and Khosla, A. (2022b). Assessing temporal correlation in environmental risk factors to design efficient area-specific COVID-19 regulations: Delhi based case study. Sci. Rep. 12 (1), 1–16. doi:10.1038/s41598-022-16781-4
Chaudhary, V., Gautam, A., Silotia, P., Malik, S., de Oliveira Hansen, R., Khalid, M., et al. (2022d). Internet-of-nano-things (IoNT) driven intelligent face masks to combat airborne health hazard. Mater. Today 60, 201–226. doi:10.1016/j.mattod.2022.08.019
Chaudhary, V., Royal, A., Chavali, M., and Yadav, S. K. (2021). Advancements in research and development to combat COVID-19 using nanotechnology. Nanotechnol. Environ. Eng. 6 (1), 8–15. doi:10.1007/s41204-021-00102-7
Chaudhary, V., Sharma, A., Bhadola, P., and Kaushik, A. (2022c). “Advancements in MXenes,” in Fundamental aspects and perspectives of MXenes (Cham: Springer), 301–324.
Chen, W. H., Strych, U., Hotez, P. J., and Bottazzi, M. E. (2020). The SARS-CoV-2 vaccine pipeline: An overview. Curr. Trop. Med. Rep. 7 (2), 61–64. doi:10.1007/s40475-020-00201-6
Chen, Z., Sivaparthipan, C. B., and Muthu, B. (2022). IoT based smart and intelligent smart city energy optimization. Sustain. Energy Technol. Assessments 49, 101724. doi:10.1016/j.seta.2021.101724
Cherusseri, J., Savio, C. M., Khalid, M., Chaudhary, V., Numan, A., and Varma, S. J. (2022). SARS-CoV-2-on-Chip for Long COVID Management. Biosensors 12 (10), 890
Chhikara, B. S., Rathi, B., Singh, J., and Poonam, F. N. U. (2020). Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics. Chem. Biol. Lett. 7 (1), 63–72.
Chintagunta, A. D., Nalluru, S., and Ns, S. K. (2021). Nanotechnology: An emerging approach to combat COVID-19. emergent Mat. 4 (1), 119–130. doi:10.1007/s42247-021-00178-6
Clifton, W., Damon, A., and Martin, A. K. (2020). Considerations and cautions for three-dimensional-printed personal protective equipment in the COVID-19 crisis. 3D Print. Addit. Manuf. 7 (3), 97–99. doi:10.1089/3dp.2020.0101
Cucinotta, D., and Vanelli, M. (2020). WHO declares COVID-19 a pandemic. Acta Biomed. 91 (1), 157–160. doi:10.23750/abm.v91i1.9397
Dao, T. L., Hoang, V. T., and Gautret, P. (2021). Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: A narrative review. Eur. J. Clin. Microbiol. Infect. Dis. 40 (1), 13–25. doi:10.1007/s10096-020-04088-z
Delshadi, R., Bahrami, A., McClements, D. J., Moore, M. D., and Williams, L. (2021). Development of nanoparticle-delivery systems for antiviral agents: A review. J. Control. Release 331, 30–44. doi:10.1016/j.jconrel.2021.01.017
Devadasu, V. R., Bhardwaj, V., and Kumar, M. R. (2013). Can controversial nanotechnology promise drug delivery? Chem. Rev. 113 (3), 1686–1735. doi:10.1021/cr300047q
Di Giampaolo, L., Zaccariello, G., Benedetti, A., Vecchiotti, G., Caposano, F., Sabbioni, E., et al. (2021). Genotoxicity and immunotoxicity of titanium dioxide-embedded mesoporous silica nanoparticles (TiO2@ MSN) in primary peripheral human blood mononuclear cells (PBMC). Nanomaterials 11 (2), 270. doi:10.3390/nano11020270
Dwivedi, Y. K., Hughes, L., Ismagilova, E., Aarts, G., Coombs, C., and Crick, T. (2021). Artificial Intelligence (AI): Multidisciplinary perspectives on emerging challenges, opportunities, and agenda for research, practice and policy. IJIM 57, 101994
El-Sayed, A., and Kamel, M. (2020). Advances in nanomedical applications: Diagnostic, therapeutic, immunization, and vaccine production. Environ. Sci. Pollut. Res. 27 (16), 19200–19213. doi:10.1007/s11356-019-06459-2
Esmaeilzadeh, A., Rostami, S., Yeganeh, P. M., Tahmasebi, S., and Ahmadi, M. (2021). Recent advances in antibody-based immunotherapy strategies for COVID-19. J. Cell. Biochem. 122 (10), 1389–1412. doi:10.1002/jcb.30017
Fernandes, R. S., de Oliveira Silva, J., Gomes, K. B., Azevedo, R. B., Townsend, D. M., de Paula Sabino, A., et al. (2022). Recent advances in point of care testing for COVID-19 detection. Biomed. Pharmacother. 153, 113538. doi:10.1016/j.biopha.2022.113538
Forouzandeh, P., O'Dowd, K., and Pillai, S. C. (2021). Face masks and respirators in the fight against the COVID-19 pandemic: An overview of the standards and testing methods. Saf. Sci. 133, 104995. doi:10.1016/j.ssci.2020.104995
Gage, A., Brunson, K., Morris, K., Wallen, S. L., Dhau, J., and Gohel, H. (2021). Perspectives of manipulative and high-performance nanosystems to manage consequences of emerging new severe acute respiratory syndrome coronavirus 2 variants. Front. nanotechnol. 3
Ganesapillai, M., Mondal, B., Sarkar, I., Sinha, A., Ray, S. S., Kwon, Y. N., et al. (2022). The face behind the Covid-19 mask-A comprehensive review. Environ. Technol. Innovation 28, 102837. doi:10.1016/j.eti.2022.102837
Gavriatopoulou, M., Korompoki, E., Fotiou, D., Ntanasis-Stathopoulos, I., Psaltopoulou, T., Kastritis, E., et al. (2020). Organ-specific manifestations of COVID-19 infection. Clin. Exp. Med. 20 (4), 493–506. doi:10.1007/s10238-020-00648-x
Gera, M., Sharma, N., Ghosh, M., Lee, S. J., Min, T., Kwon, T., et al. (2017). Nanoformulations of curcumin: An emerging paradigm for improved remedial application. Oncotarget 8 (39), 66680–66698. doi:10.18632/oncotarget.19164
Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K., et al. (2020). Delivering the power of nanomedicine to patients today. J. Control. Release 326, 164–171. doi:10.1016/j.jconrel.2020.07.007
Goscianska, J., Freund, R., and Wuttke, S. (2022). Nanoscience versus viruses: The SARS-CoV-2 case. Adv. Funct. Mat. 32 (14), 2107826. doi:10.1002/adfm.202107826
Haleem, A., Javaid, M., Suman, R., and Singh, R. P. (2021). 3D printing applications for radiology: An overview. Indian J. Radiol. Imaging 31 (01), 010–017. doi:10.1055/s-0041-1729129
Harish, V., Tewari, D., Gaur, M., Yadav, A. B., Swaroop, S., Bechelany, M., et al. (2022). Review on nanoparticles and nanostructured materials: Bioimaging, biosensing, drug delivery, tissue engineering, antimicrobial, and agro-food applications. Nanomater. (Basel, Switz. 12 (3), 457. doi:10.3390/nano12030457
Hashemi, B., Akram, F. A., Amirazad, H., Dadashpour, M., Sheervalilou, M., Nasrabadi, D., et al. (2021). Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. J. Drug Deliv. Sci. Technol. 67, 102967. doi:10.1016/j.jddst.2021.102967
Hu, B., Guo, H., Zhou, P., and Shi, Z. L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology 19 (3), 141–154.
Irfan Ul Haq, M., Khuroo, S., Raina, A., Khajuria, S., Javaid, M., Farhan Ul Haq, M., et al. (2020). 3D printing for development of medical equipment amidst coronavirus (COVID-19) pandemic—Review and advancements. Res. Biomed. Eng. 38, 305–315. doi:10.1007/s42600-020-00098-0
Ishikawa, F. N., Chang, H. K., Curreli, M., Liao, H. I., Olson, C. A., Chen, P. C., et al. (2009). Label-free, electrical detection of the SARS virus N-protein with nanowire biosensors utilizing antibody mimics as capture probes. ACS Nano 3 (5), 1219–1224. doi:10.1021/nn900086c
Jackman, J. A., Lee, J., and Cho, N. J. (2016). Nanomedicine for infectious disease applications: Innovation towards broad-spectrum treatment of viral infections. Small 12 (9), 1133–1139. doi:10.1002/smll.201500854
Javaid, M., and Haleem, A. (2021). 3D bioprinting applications for the printing of skin: A brief study. Sensors Int. 2, 100123. doi:10.1016/j.sintl.2021.100123
Jayant, R. D., Tiwari, S., Atluri, V., Kaushik, A., Tomitaka, A., Yndart, A., et al. (2018). Multifunctional nanotherapeutics for the treatment of neuroAIDS in drug abusers. Sci. Rep. 8 (1), 1–12. doi:10.1038/s41598-018-31285-w
Jurischka, C., Dinter, F., Efimova, A., Weiss, R., Schiebel, J., Schulz, C., et al. (2020). An explorative study of polymers for 3D printing of bioanalytical test systems. Clin. Hemorheol. Microcirc. 75 (1), 57–84. doi:10.3233/ch-190713
Kamat, S., Kumari, M., and Jayabaskaran, C. (2021). Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2. J. Control. Release 338, 813–836. doi:10.1016/j.jconrel.2021.08.046
Karimi, M., Eslami, M., Sahandi-Zangabad, P., Mirab, F., Farajisafiloo, N., Shafaei, Z., et al. (2016). pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. WIREs Nanomed. Nanobiotechnol. 8 (5), 696–716. doi:10.1002/wnan.1389
Katkar, R. A., Taft, R. M., and Grant, G. T. (2018). 3D volume rendering and 3D printing (additive manufacturing). Dent. Clin. North Am. 62 (3), 393–402. doi:10.1016/j.cden.2018.03.003
Kaushik, A., Jayant, R. D., Bhardwaj, V., and Nair, M. (2018). Personalized nanomedicine for CNS diseases. Drug Discov. today 23 (5), 1007–1015. doi:10.1016/j.drudis.2017.11.010
Kaushik, A. (2021). Manipulative magnetic nanomedicine: The future of COVID-19 pandemic/endemic therapy. Expert Opin. Drug Deliv. 18 (5), 531–534. doi:10.1080/17425247.2021.1860938
Kaushik, A., Yndart, A., Atluri, V., Tiwari, S., Tomitaka, A., Gupta, P., et al. (2019). Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection. Sci. Rep. 9 (1), 1–11. doi:10.1038/s41598-019-40222-4
Kim, J. H., Lee, S., Park, E. R., and Jang, W. C. (2022). Development of a highly sensitive and rapid detection method for Pea enation mosaic virus using loop-mediated isothermal amplification assay. J. Virological Methods 300, 114427. doi:10.1016/j.jviromet.2021.114427
Konwar, A. N., and Borse, V. (2020). Current status of point-of-care diagnostic devices in the Indian healthcare system with an update on COVID-19 pandemic. Sensors Int. 1, 100015. doi:10.1016/j.sintl.2020.100015
Koo, J. R., Cook, A. R., Park, M., Sun, Y., Sun, H., Lim, J. T., et al. (2020). Interventions to mitigate early spread of SARS-CoV-2 in Singapore: A modelling study. Lancet Infect. Dis. 20 (6), 678–688. doi:10.1016/s1473-3099(20)30162-6
Krishnan, S., Dusane, A., Morajkar, R., Venkat, A., and Vernekar, A. A. (2021). Deciphering the role of nanostructured materials in the point-of-care diagnostics for COVID-19: A comprehensive review. J. Mat. Chem. B 9 (30), 5967–5981. doi:10.1039/d1tb01182k
Larrañeta, E., Dominguez-Robles, J., and Lamprou, D. A. (2020). Additive manufacturing can assist in the fight against COVID-19 and other pandemics and impact on the global supply chain. 3D Print. Addit. Manuf. 7 (3), 100–103. doi:10.1089/3dp.2020.0106
Lembo, D., Donalisio, M., Civra, A., Argenziano, M., and Cavalli, R. (2018). Nanomedicine formulations for the delivery of antiviral drugs: A promising solution for the treatment of viral infections. Expert Opin. Drug Deliv. 15 (1), 93–114. doi:10.1080/17425247.2017.1360863
MacIntyre, C. R., and Chughtai, A. A. (2020). A rapid systematic review of the efficacy of face masks and respirators against coronaviruses and other respiratory transmissible viruses for the community, healthcare workers and sick patients. Int. J. Nurs. Stud. 108, 103629. doi:10.1016/j.ijnurstu.2020.103629
Mainardes, R. M., and Diedrich, C. (2020). The potential role of nanomedicine on COVID-19 therapeutics. Ther. Deliv. 11 (7), 411–414. doi:10.4155/tde-2020-0069
Manickam, P., Mariappan, S. A., Murugesan, S. M., Hansda, S., Kaushik, A., Shinde, R., et al. (2022). Artificial intelligence (AI) and internet of medical things (IoMT) assisted biomedical systems for intelligent healthcare. Biosensors 12 (8), 562. doi:10.3390/bios12080562
Markandan, K., Tiong, Y. W., Sankaran, R., Subramanian, S., Markandan, U. D., Chaudhary, V., et al. (2022). Emergence of infectious diseases and role of advanced nanomaterials in point-of-care diagnostics: A review. Biotechnol. Genet. Eng. Rev. 38 (1), 1–89. doi:10.1080/02648725.2022.2127070
Marro, A., Bandukwala, T., and Mak, W. (2016). Three-dimensional printing and medical imaging: A review of the methods and applications. Curr. problems diagnostic radiology 45 (1), 2–9. doi:10.1067/j.cpradiol.2015.07.009
Martínez-Paredes, G., González-García, M. B., and Costa-García, A. (2009). Genosensor for SARS virus detection based on gold nanostructured screen-printed carbon electrodes. Electroanalysis 21 (3-5), 379–385. doi:10.1002/elan.200804399
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., and Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20 (2), 101–124. doi:10.1038/s41573-020-0090-8
Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2005). Nanomedicine: Current status and future prospects. FASEB J. 19 (3), 311–330. doi:10.1096/fj.04-2747rev
Mohammadi, K., Sani, M. A., Azizi-Lalabadi, M., and McClements, D. J. (2022). Nano-enabled personalized nutrition: Developing multicomponent-bioactive colloidal delivery systems. Adv. colloid interface Sci. 282, 102211. doi:10.1016/j.cis.2020.102211
Mohammadi Pour, P., Fakhri, S., Asgary, S., Farzaei, M. H., and Echeverria, J. (2019). The signaling pathways, and therapeutic targets of antiviral agents: Focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front. Pharmacol. 10, 1207. doi:10.3389/fphar.2019.01207
Mokhtarzadeh, A., Eivazzadeh-Keihan, R., Pashazadeh, P., Hejazi, M., Gharaatifar, N., Hasanzadeh, M, et al. (2017). Nanomaterial-based biosensors for detection of pathogenic virus. TrAC Trends Anal. Chem. 97, 445–457. doi:10.1016/j.trac.2017.10.005
Mujawar, M. A., Gohel, H., Bhardwaj, S. K., Srinivasan, S., Hickman, N., and Kaushik, A. (2020). Nano-enabled biosensing systems for intelligent healthcare: Towards COVID-19 management. Mater. Today Chem. 17, 100306. doi:10.1016/j.mtchem.2020.100306
Munaz, A., Vadivelu, R. K., John, J. S., Barton, M., Kamble, H., and Nguyen, N. T. (2016). Three-dimensional printing of biological matters. J. Sci. Adv. Mater. Devices 1 (1), 1–17. doi:10.1016/j.jsamd.2016.04.001
Naghdi, M., Ghovvati, M., Rabiee, N., Ahmadi, S., Abbariki, N., Sojdeh, S., et al. (2022). Magnetic nanostructures in nanomedicine revolution: A review of growing magnetic nanocomposites in biomedical applications. Adv. Colloid Interface Sci. 308, 102771. doi:10.1016/j.cis.2022.102771
Noh, E. Y., Park, Y. H., Chai, Y. J., Kim, H. J., and Kim, E. (2022). Frontline nurses’ burnout and its associated factors during the COVID-19 pandemic in South Korea. Applied Nursing Research 67, 151622
Oroojalian, F., Haghbin, A., Baradaran, B., Hemmat, N., Shahbazi, M. A., Baghi, H. B., et al. (2020). Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. Int. J. Biol. Macromol. 165, 18–43. doi:10.1016/j.ijbiomac.2020.09.204
Pandey, A., Nikam, A. N., Shreya, A. B., Mutalik, S. P., Gopalan, D., Kulkarni, S., et al. (2020). Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sci. 256, 117883. doi:10.1016/j.lfs.2020.117883
Pandian, S. R. K., Panneerselvam, T., Pavadai, P., Govindaraj, S., Ravishankar, V., Palanisamy, P., et al. (2021). Nano based approach for the treatment of neglected tropical diseases. Front. Nanotechnol. 3, 665274. doi:10.3389/fnano.2021.665274
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., et al. (2018). Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnology 16 (1), 71–33. doi:10.1186/s12951-018-0392-8
Praditya, D., Kirchhoff, L., Brüning, J., Rachmawati, H., Steinmann, J., and Steinmann, E. (2019). Anti-infective properties of the golden spice curcumin. Front. Microbiol. 10, 912. doi:10.3389/fmicb.2019.00912
Rabaan, A. A., Al-Ahmed, S. H., Muhammad, J., Khan, A., Sule, A. A., Tirupathi, R., et al. (2021). Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines 9 (5), 436. doi:10.3390/vaccines9050436
Rai, M., Bonde, S., Yadav, A., Bhowmik, A., Rathod, S., Ingle, P., et al. (2021). Nanotechnology as a shield against COVID-19: Current advancement and limitations. Viruses 13 (7), 1224. doi:10.3390/v13071224
Rashidzadeh, H., Danafar, H., Rahimi, H., Mozafari, F., Salehiabar, M., Rahmati, M. A., et al. (2021). Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): Diagnosis, treatment, therapy and future perspectives. Nanomedicine 16 (6), 497–516. doi:10.2217/nnm-2020-0441
Revuelta-Herrero, J. L., Chamorro-de-Vega, E., Rodríguez-González, C. G., Alonso, R., Herranz-Alonso, A., and Sanjurjo-Sáez, M. (2018). Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann. Pharmacother. 52 (1), 11–18. doi:10.1177/1060028017728294
Ruiz-Hitzky, E., Darder, M., Wicklein, B., Ruiz-Garcia, C., Martín-Sampedro, R., Del Real, G., et al. (2020). Nanotechnology responses to COVID-19. Adv. Healthc. Mat. 9 (19), 2000979. doi:10.1002/adhm.202000979
Sadeghi, A., Tahmasebi, S., Mahmood, A., Kuznetsova, M., Valizadeh, H., Taghizadieh, A., et al. (2021). Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J. Cell. Physiol. 236 (4), 2829–2839. doi:10.1002/jcp.30047
Saha, R. P., Sharma, A. R., Singh, M. K., Samanta, S., Bhakta, S., Mandal, S., et al. (2020). Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front. Pharmacol. 11, 1258. doi:10.3389/fphar.2020.01258
Saylan, Y., and Denizli, A. (2020). “Virus detection using nanosensors,” in Nanosensors for smart cities (Amsterdam, Netherlands: Elsevier), 501–511.
Shan, B., Broza, Y. Y., Li, W., Wang, Y., Wu, S., Liu, Z., et al. (2020). Multiplexed nanomaterial-based sensor array for detection of COVID-19 in exhaled breath. ACS Nano 14 (9), 12125–12132. doi:10.1021/acsnano.0c05657
Sheth, Y., Dharaskar, S., Chaudhary, V., Khalid, M., and Walvekar, R. (2022). Prospects of titanium carbide-based MXene in heavy metal ion and radionuclide adsorption for wastewater remediation: A review. Chemosphere 293, 133563. doi:10.1016/j.chemosphere.2022.133563
Singh, A. P., Biswas, A., Shukla, A., and Maiti, P. (2019). Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct. Target. Ther. 4 (1), 33–21. doi:10.1038/s41392-019-0068-3
Singh, L., Kruger, H. G., Maguire, G. E., Govender, T., and Parboosing, R. (2017). The role of nanotechnology in the treatment of viral infections. Ther. Adv. Infect. Dis. 4 (4), 105–131. doi:10.1177/2049936117713593
Sodhi, K. K., and Singh, C. K. (2022). A systematic review on the occurrence, fate, and reeixeiramediation of SARS-CoV-2 in wastewater. Int. J. Environ. Sci. Technol. 19, 1–14. doi:10.1007/s13762-022-04326-1
Sportelli, M. C., Izzi, M., Kukushkina, E. A., Hossain, S. I., Picca, R. A., Ditaranto, N., et al. (2020). Can nanotechnology and materials science help the fight against SARS-CoV-2? Nanomaterials 10 (4), 802. doi:10.3390/nano10040802
Strasfeld, L., and Chou, S. (2010). Antiviral drug resistance: Mechanisms and clinical implications. Infect. Dis. Clin. North Am. 24 (3), 809–833. doi:10.1016/j.idc.2010.07.001
Swaminathan, S., Cavalli, R., and Trotta, F. (2016). Cyclodextrin-based nanosponges: A versatile platform for cancer nanotherapeutics development. WIREs Nanomed. Nanobiotechnol. 8 (4), 579–601. doi:10.1002/wnan.1384
Szunerits, S., Barras, A., Khanal, M., Pagneux, Q., and Boukherroub, R. (2015). Nanostructures for the inhibition of viral infections. Molecules 20 (8), 14051–14081. doi:10.3390/molecules200814051
Tannous, M., Trotta, F., and Cavalli, R. (2020). Nanosponges for combination drug therapy: State-of-the-art and future directions. Nanomedicine 15 (07), 643–646. doi:10.2217/nnm-2020-0007
Teixeira, M. C., Sanchez-Lopez, E., Espina, M., Calpena, A. C., Silva, A. M., and Veiga, F. J., (2018). “Advances in antibiotic nanotherapy: Overcoming antimicrobial resistance,” in Emerging Nanotechnologies in Immunology. Editors R. Shegokar, and E. D. Souto (Boston, MA: Elsevier), 233–259.
Tino, R., Moore, R., Antoline, S., Ravi, P., Wake, N., Ionita, C. N., et al. (2020). COVID-19 and the role of 3D printing in medicine. 3D Print. Med. 6 (1), 11. doi:10.1186/s41205-020-00064-7
Tomitaka, A., Kaushik, A., Kevadiya, B. D., Mukadam, I., Gendelman, H. E., Khalili, K., et al. (2019). Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. Drug Discov. Today 24 (3), 873–882. doi:10.1016/j.drudis.2019.01.006
Umapathi, R., Sonwal, S., Lee, M. J., Rani, G. M., Lee, E. S., Jeon, T. J., et al. (2021). Colorimetric based on-site sensing strategies for the rapid detection of pesticides in agricultural foods: New horizons, perspectives, and challenges. Coord. Chem. Rev. 446, 214061. doi:10.1016/j.ccr.2021.214061
Vahedifard, F., and Chakravarthy, K. (2021). Nanomedicine for COVID-19: The role of nanotechnology in the treatment and diagnosis of COVID-19. emergent Mat. 4 (1), 75–99. doi:10.1007/s42247-021-00168-8
Varahachalam, S. P., Lahooti, B., Chamaneh, M., Bagchi, S., Chhibber, T., Morris, K., et al. (2021). Nanomedicine for the SARS-CoV-2: State-of-the-art and future prospects. Int. J. Nanomedicine 16, 539–560. doi:10.2147/ijn.s283686
Vazquez-Munoz, R., and Lopez-Ribot, J. L. (2020). Nanotechnology as an alternative to reduce the spread of COVID-19. Challenges 11 (2), 15. doi:10.3390/challe11020015
Verma, N., and Bhardwaj, A. (2015). Biosensor technology for pesticides—a review. Appl. Biochem. Biotechnol. 175 (6), 3093–3119.
Vijayan, V., Mohapatra, A., Uthaman, S., and Park, I. K. (2019). Recent advances in nanovaccines using biomimetic immunomodulatory materials. Pharmaceutics 11 (10), 534. doi:10.3390/pharmaceutics11100534
Watkins, R., Wu, L., Zhang, C., Davis, R. M., and Xu, B. (2015). Natural product-based nanomedicine: Recent advances and issues. Int. J. Nanomedicine 10, 6055–6074. doi:10.2147/ijn.s92162
Wei, T., Cheng, Q., Min, Y. L., Olson, E. N., and Siegwart, D. J. (2020). Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 11 (1), 1–12. doi:10.1038/s41467-020-17029-3
Widjaja, G., Jalil, A. T., Rahman, H. S., Abdelbasset, W. K., Bokov, D. O., Suksatan, W., et al. (2021). Humoral immune mechanisms involved in protective and pathological immunity during COVID-19. Hum. Immunol. 82 (10), 733–745. doi:10.1016/j.humimm.2021.06.011
Wu, F., Xiao, A., Zhang, J., Moniz, K., Endo, N., and Armas, F. (2021). SARS-CoV-2 RNA concentrations in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases. Science of The Total Environment 805, 150121
Xu J, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., et al. (2020). Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 12 (2), 244. doi:10.3390/v12020244
Xu L, L., Li, D., Ramadan, S., Li, Y., and Klein, N. (2020). Facile biosensors for rapid detection of COVID-19. Biosens. Bioelectron. 170, 112673. doi:10.1016/j.bios.2020.112673
Yayehrad, A. T., Siraj, E. A., Wondie, G. B., Alemie, A. A., Derseh, M. T., and Ambaye, A. S. (2021). Could nanotechnology help to end the fight against COVID-19? Review of current findings, challenges and future perspectives. Int. J. Nanomedicine 16, 5713–5743. doi:10.2147/ijn.s327334
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., and Kutlu, O. (2020). Therapeutic nanoparticles and their targeted delivery applications. Molecules 25 (9), 2193. doi:10.3390/molecules25092193
Keywords: COVID-19, nanomedicine, nanotechnology, pandemic, SARS-CoV-2
Citation: Singh CK and Sodhi KK (2023) The emerging significance of nanomedicine-based approaches to fighting COVID-19 variants of concern: A perspective on the nanotechnology’s role in COVID-19 diagnosis and treatment. Front. Nanotechnol. 4:1084033. doi: 10.3389/fnano.2022.1084033
Received: 29 October 2022; Accepted: 02 December 2022;
Published: 06 January 2023.
Edited by:
Ajeet Kaushik, Florida Polytechnic University, United StatesCopyright © 2023 Singh and Sodhi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kushneet Kaur Sodhi, kushneetsodhi936@gmail.com